Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://biz.yahoo.com/bw/080616/20080616006407.html?.v=1
Just to offer Orasure's rebuttal. As far as I'm concerned this test is still just as accurate as any blood test.
Thanks OR. I noticed Sumit added the Calypte Life Science products as well to their website. I read through the meeting minutes and found it pretty interesting. Looks like many distributors had issues with the qualifications. I think its just a matter of cost now and being able to convince them that an OMT test is somehow less expensive in the long run and more people perfer it. I can see them using a small portion of their funds to try it out - perhaps 200,000 or so tests (which would represent a little over 2% of the 9mil tests). Well, good luck to them.
P.S. - I think that having their manufacturing plant in China may hurt them (as opposed to directly in India).
Thanks for reminding us...that was a total joke. I think it made Mineseeker look bad as well, reneging on helping Africa with thier HIV/AIDS problem.
right on...
Hopefully its like a job interview where they provide a whole list of prerequisites and specifications, but in the end will still take who they think might do the job the best even though they don't meet all the requirements.
It's a catch-22. How do you land a first sale if they will only contract to people that already have large sales?
Initial first test. Necessary confirmation tests, will be done as needed (ELISA, etc.)
I have read the Techincial Specs starting at page 80. Is this what you are referring to? And if so, what specifications can Calypte not meet?
They definately comply with 1,2,3,5,6a,6c,7,9,10.
Not sure about 4 and 6b.
As far as #8 goes, I'm sure they could figure something out.
http://www.unops.org/UNOPS/UserControls/BO/File.aspx/NACP-III%20-HIV%20Rapid-1st%20Test.doc?AttachmentID=db190667-d0d3-4087-bf98-8939c8ce2540
They better be at least submitting a bid. I believe this is for over 9 million tests.
Looks like they found out everyone was sort of making fun of their "news" update and they decided to remove it from the sight. I no longer see it out there...maybe they are revamping it.
"From now on, the company's development will entre into a new stage. We anticipate creating a miracle in China!"
Let's hope so. It will be a miracle if they can create this miracle.
First of all, I'm not sure we can conclude that Calypte's test is the most expensive. Secondly, the reason for the shortage is that they had to pull all these cheap tests out of the market because they weren't accurate. So obviously, they aren't going to purchase from those vendors anymore. Hopefully some sort of cost effectiveness comparison also goes into their decision.
540,875 traded @.04
50,000 traded @.045
35,000 traded @.046
So, it looks like about of of that large trade was at .04 and half at .05. Someone was willing to sell @.04. Who and why? I'm hoping it's just stop losses being taking out.
You're right. In 05 there was a 1 for 4 reverse split.
Thanks for your thoughts SellHigh. As far as the chart goes, it looks great if you like those with a pattern and can time things right. It's gone from 5-10 to 20 and least 3 times - nice repeating cycle...not a great long term chart though I agree.
Anyone follow TRIB or OSUR. Both seem to be stuggling in the African market. I can't believe TRIB is only valued at $63 million and OSUR is valued somewhere around $254 million. TRIB constitanly has generated more revenues and higher earnings in recent years. I might start taking a look at purchasing some shares in TRIB, seems undervalued at this point. In comparison CBMC is valued at roughly $20 million with no sales and negative earnings.
Good news is needed now more than ever...what is going on Roger?
And the test they are using?
TGIF - Do they come any other way?
Here's a better email address: Rgale@calypte.com
Blood - As far as your mock letter goes, is there a specific reason you would ask SF Capital to setup a meeting? Do they have a connection to the Gates Foundation? As far as the Gates Foundation goes, I know they are spending Billions on trying to develop a vaccine and that is their primary goal. Their second goal is to create "Microbicides–gels or creams that women could apply to protect themselves from sexually acquired HIV infection"
Seriously!?! Who wants to rub cream all over them self prior to being intimate (besides whip cream of course)
I agree that the only way Calypte will ever make it is to partner with a large NGO such as the GF or CF. They are not going to sell the tests themselves or with the help of small time distributors.
What better way then to release a PR announcing a partnership with the Gates Foundation and an initial 5 million test purchase. That should keep it above .052 for awhile.
In our dreams.
What? Sorry OR, I'm not following you on this thread.
Which one? I always thought you sounded a bit foreign.
Marr could have closed on collateral in 2007 but elected not to. I think their interests in the agreement lie elsewhere to the take over of Calypte collateral.
Anyone live in D.C. or Boston? http://www.calyptelifesciences.com/
http://gm.asm.org/ie.asp
http://www.aacc.org/events/ann_meet/Pages/default.aspx
I smile and a sense of joy covers my face. Calypte is going to reach 15 million in revenue this year!!!
P.S. - I'm being cynical
No, but we can assume that the combination of the SA order and the Indian order total $36,000.
158% increase year over year in Rapid HIV test!!!
TIC - (Like Dilbert's comic)
Appears as though Orasure is having some issues. I suggest listening to their most recent CC. They recently lost a large client for their Orasure Oral Test in Madacascar due to funding source changes (not willing to pay more for the oral test). They also mentioned East Africa (Kenya, Uganda) initiatives are delayed due to political unrest but they are still confident revenue will begin once stability occurs. I would assume this is the same initiative Calypte was involved in (If you remember they were to use both tests). They also mentioned that they are hoping to enter the Russian market, but no mention of China or India.
Well you can't fault them for their lack of marketing effort prior to approval in China. Looks like they really made the rounds between August and December of 2007. Wonder what has been going on the past 5 months and why there isn't more promotion/articles regarding the approval (not even listed under "Product News").
P.S. - I thought David Harris was going to be, well, more Asian.
We already know this is the case. It's already been said.
No one? Well I'll look into it and report back. I'm surprised there has been a press release regarding this new initiative. Perhaps they are waiting until the 1st quarter results to announce this new undertaking.
What is this? Seems like a subsidary of Calypte, called "Calypte Life Sciences". I do like the website, hopefully they will also change their corporate one as well...it needs an overhaul.
Calypte is now trying to sell recombinant proteins, antigens, blockers, plate coats, platewashes, additives, diluents, clearants, buffers, and conjugates. Anyone familiar with this market that could provide some information?
I assume you are implying that I am wrong:
I know that Calypte has the only officially approved OMT HIV tset in India, that's why its sad that Orasure tests seem to get more publicity and recognition than Calypte's test (which is already approved).
India must allow un-approved tests to be used for research programs (the test is FDA approved so I don't think they have too many worries).
The same Medical group and doctor did a similiar test about a year ago in India:
http://timesofindia.indiatimes.com/NEWS/India/20-min_oral_test_to_detect_hiv/articleshow/1900677.cms
My question is why don't they use Calypte's test instead of Orasures.
It's most likely Orasure's Advance test. The same doctor did a study using Orasure's test last year. It also mentions that a reactive result shows a purple line, which would conincide with Orasure's test. I am not aware of what color line Calypte's would show.
Either way, I think it paves way for positive feedback for OMT HIV tests.
http://slimconomy.blogspot.com/
Blogger, with experience, writes article regarding China approval. There is also a blog below it relating to China and the market there.
????? Are you implying Calypte told this small Online Equity researcher about the imending approval? You gotta be kidding. Buy recs are always done following news, earnings releases, material events, etc. Did you not read it? They discuss the approval. The didn't place the buy rec on it until after the news release. How do you think Coverage on stocks are initiated?
Pretty generic, but thought I'd post it anyway. This is from Bellwetherreport.Com
Yesterday we had a conversation with Brian Sozzi of Wall Street Strategies, to ask his professional opinion on Calypte Biomedical Corp. (OTCBB:CBMC).
Brief Description:
The company engages in the development, manufacture, and distribution of in vitro diagnostic tests, primarily for the diagnosis of human immunodeficiency virus (HIV) infection.
This conversation was conducted on April 17th 2008.
Q: What’s your current take on the pharmaceutical industry in China as compared to Chinese online gaming?
A: Chinese online gaming, sure it’s alive, but investing in the space has died down. Next hotspot you wonder? Developing medical products for the runaway population in China looks to be a surefire way to bank some profits.
Q: So, what’s your opinion of Calypte Biomedical?
A: Today, the company announced that its Chinese subsidiary, Beijing Marr Bio-Pharmaceutical Co. Ltd., has received registration and marketing approval for its Aware HIV-1/2 OMT (oral fluid) rapid test from the State Food and Drug Administration of China.
Q: What more can you tell us about this approval?
A: This approval makes the Aware HIV-1/2 OMT test the first and only SFDA approved rapid oral fluid HIV test in China. We agree with management that the approval is a “major” development for the company, so much so, in our view the stock has significant room to the upside as the company begins marketing the product immediately.
Q: What would you tell investors looking to position themselves in this stock?
A: The opportunities to leverage the product are almost endless given the Chinese population characteristics and hurried increase in HIV in the country.
Bellwether Report and Wall Street Strategies do not own any stock in Calypte Biomedical Corp. (OTCBB:CBMC), nor do we have any vested interested in the company, nor have we been paid by the company or any third party affiliate of the company. Bellwether Report and Wall Street Strategies have received no remuneration for this report, it’s simply to assist investors when doing their own research on this equity. This is only an opinion and is completely unbiased.
Potential in 2-3 years is extremely high. The "potential" for a company with a new, innovative product with limited competition is always very high. With the large outstanding share count, the rise in PPS will of course be diminished. The potential has always been there with this company, they just haven't been able to deliver. Imagine how difficult it is to try to penetrate international markets such as India, China, Afria with a staff of only 10-15 and little to no constant capital. These markets are hard to do business in. They need to land approval in the U.S. and hopefully the U.S. will approve OTC versions of HIV tests. If (and its a huge if) that can happen over the next few years, I see this stock being somewhere around $1.50 - $2 (without any reverse split). Of course this would be the best case scenario. A more likely scenario is that the company continues to generate little revenue and goes belly up.
Hey blood, do you remember if there was any clause in the Fusion Capital deal that refers to reverse splits? Does the .052 minimum price just carry into the new conversion price after the split?
"We have already received numerous inquiries from HIV program managers and scientists eager to use the product here in China." - Lets see how long it takes for them to deliver.
Did anyone see that Orasure is being sued by Inverness? Sounds like a lengthy, costly battle.
Hey all! Happy to come home to some good news (finally) - was shooting some scenes for Michael Mann's/Johnny Depp's new movie "Public Enemies". Haven't had a chance to dig in and go through everything yet, so I'll start by asking you all: Was there any mention of OTC? Does this approval give Calypte/Marr the ability to sell the test over the counter? What is China's policy in regards to OTC HIV tests? Calypte does have the Aware OTC version available of course and I am curious if they can use that version in China. Answers/Comments? TIA and congrats to Calypte for finally coming through.
Wow, they really work the "attractive people sell products" marketing campaign don't they? Second picture above. Not going near this product (or stock)...best of luck to you all though.
I think as well, the main point was to raise the outstanding share account and place notice that a certain amount of shares were sold to Fusion in order to raise $350,0000.
OR, what do you mean by that?
Prospectuses are rereleased when deemed necessary by the company, typically when certain developements have changed and make the old prospective obsolete. Sorry, not enough time to look through it now. Blood, wanna take a look at report back with any differences between today's release at the one in Feb. TIA